Overview
US water, hygiene and infection prevention provider's Q1 sales rose 10%, beating analyst expectations
Adjusted diluted EPS for Q1 grew 13% and met analyst expectations
Company repurchased 1.3 mln shares during Q1
Outlook
Ecolab maintains 2026 adjusted diluted EPS outlook at $8.43-$8.63, up 12%-15%
Company expects Q2 2026 adjusted diluted EPS of $2.02-$2.12, up 7%-12%
Result Drivers
VALUE PRICING - Co said strong value pricing contributed to double-digit EPS growth
SEGMENT GROWTH - Accelerated growth in Life Sciences, Global High-Tech, Institutional and Specialty led organic sales gains
PRODUCTIVITY IMPROVEMENTS - Co said improved productivity helped offset higher commodity costs
Company press release: ID:nBw4JHxRra
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$4.07 bln
$4.02 bln (17 Analysts)
Q1 Adjusted EPS
Meet
$1.70
$1.70 (21 Analysts)
Q1 EPS
$1.52
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy"
Wall Street's median 12-month price target for Ecolab Inc is $327.50, about 22.3% above its April 27 closing price of $267.88
The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 31 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)